Regeneus updates on Progenza in Japan

Latest News

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, says it is on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near-term.

Progenza is the company's allogeneic, off-the-shelf stem cell product for osteoarthritis.

The company had previously disclosed it anticipated completing the collaboration before the end of 30 June. However, it says discussions have taken longer than originally anticipated.

"Part of this delay is due to there being several interested parties in active discussions for licensing Progenza," said the compamy.

The company last week it has entered into an R&D loan facility agreement and has drawn down $1 million. It said the funds will be used for operational expenditure.